Advertisement

Topics

The Incretin Secretion in the Gut System Related to the Physiological Stimulus

2014-07-23 21:12:28 | BioPortfolio

Summary

Insulin secretion and insulin sensitivity are related with an inverse, hyperbolic function, the so called disposition index, that shows the critical importance of the ß-cell dysfunction for the development of T2DM. A consequence of the hyperbolic relationship is that increased insulin resistance is compensated by up-regulation of insulin secretion, as it happens in obesity. However, when a defective insulin secretion in relation to insulin sensitivity takes place (i.e. reduced disposition index) then impaired glucose tolerance or type 2 diabetes develop. The investigators have recently demonstrated that bilio-pancreatic diversion determines a prompt reversibility of T2DM by normalizing peripheral insulin sensitivity and enhancing ß-cell sensitivity to glucose; these changes occur within few days after surgery, largely before changes in body weight occur. This operation may affect the entero-insular axis function, by diverting nutrients away from the proximal gastro-intestinal tract and by delivering incompletely digested nutrients to the ileum, thus abnormally stimulating the secretion of intestinal incretins. It has been shown that male Wistar rats undergoing three different types of small intestinal surgery, namely ileal transposition (either 10 or 20 cm of lower ileum transposed to mid-duodenum) or 85% jejuno-ileal bypass, showed a sustained post-operative reduction in food intake and a significant change in body weight gain. All experimental groups had a large increase in basal and meal-stimulated enteroglucagon, while the area under the curve of plasma levels of gastrin, gastric inhibitory polypeptide (GIP), insulin and blood glucose were significantly reduced. GIP is produced mainly in the duodenum and jejunum as shown in dogs .The aim of the present study is to investigate the intestinal site of production of incretins in response to intraluminal nutrients stimulation in order to establish the relationship between insulin resistance, insulin hypersecretion and different small intestinal segments in insulin resistance conditions, such as obesity and T2DM. To this purpose a mixed test meal will be infused in the duodenum, proximal jejunum or ileum and glucose uptake and insulin secretion studied, in relation to glucagon and incretin response. Studies are carried out in 20 obese subjects of both sexes, 10 of whom with type 2 diabetes and 10 with normal glucose tolerance.

Description

For intestinal perfusion, a tube assembly (outer diameter 7 mm) marked with a length scale is used. It consists of six tubes that are bonded together with tetrahydrofuran (Sigma Chemical Corp, St Louis, Missouri, USA). Three tubes are connected to a balloon which is used to occlude the intestinal lumen proximal to the site of infusion. Three tubes are radio-opaque to allow fluoroscopic location of the assembly; their distal end is immediately distal to the proximal occluding balloon(perfusion site) and positioned at 60 cm (duodenum), 90 cm (proximal jejunum) and 120 cm (distal jejunum) from the nose. After a 12 hour fast, the subjects swallow the tube assembly. The position of the assembly is confirmed by fluoroscopy. With the tube in the right position, the occluding balloon is inflated with 60 ml of air and perfusion of the distal intestinal segment is started. The perfusion is performed for 30 minutes of the test period, which is followed by a 120 minute absorption period. Each subject will be studied in 3 different sessions at 7-10 days distance randomly selected in order to study the effect on insulin sensitivity and secretion of a test meal delivery in different intestinal segments (i.e. at the duodenum, the proximal jejunum, and the distal jejunum). Blood samples for glucose, free fatty acids (FFA) insulin, C-peptide, glucagon, GLP-1, GIP, are drawn at -30 minutes and at 0, 15, 30, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 minutes during each of the test periods. The lipid-glucose-protein test meal is a mixture of ScandiShake(85 g of powder is mixed in 240-mL milk resulting in 69.5 g carbohydrates, 30.4 g fat, and 11.7 g protein).

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Conditions

Obesity

Location

Department of Metabolic Diseases, Institute of Internal Medicine - Catholic University
Rome
Italy
00168

Status

Recruiting

Source

Catholic University of the Sacred Heart

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:12:28-0400

Clinical Trials [631 Associated Clinical Trials listed on BioPortfolio]

Re-Energize With Nutrition, Exercise and Weight Loss

The purpose of this project is to establish a Center of Excellence in Research on Obesity that will focus on severe obesity. The prevalence of severe obesity (i.e., Class 2 and 3 obesity;...

Awareness, Care & Treatment In Obesity Management - An International Observation

The purpose of this survey is to collect the data on perceptions, behaviours and awareness related to obesity and obesity management for People with Obesity (PwO) and Health Care Professio...

Inflammation, Diabetes, Ethnicity and Obesity Cohort

Obesity affects over one third of US adults (>72 million, with BMI ≥30 kg/m2), and the proportion of US adults with BMI ≥40 kg/m2 has doubled in the last 20 years. Obesity is associate...

Comparison of Workplace Obesity Management Programs

The purpose of this study is to design and demonstrate the feasibility of implementing moderate and intensive environmental obesity prevention programs at major worksites.

Community-based Obesity Treatment in African American Women After Childbirth

The purpose of this study is to determine the effect of the community-based obesity treatment (PP), compared to usual care (UC), on changes in maternal weight over 12 months.

PubMed Articles [2573 Associated PubMed Articles listed on BioPortfolio]

Association of FTO rs9939609 with Obesity.

Association of FTO rs9939609 with Obesity Association of FTO rs9939609 with Obesity Association of FTO rs9939609 with Obesity Association of FTO rs9939609 with Obesity Association of FTO rs9939609 wit...

Prevalence and Determinants of Engagement with Obesity Care in the United States.

Medical management of obesity can result in significant weight loss and reduce the burden of obesity-related complications. This report employs a new conceptual model to quantify engagement with obesi...

Epidemiology of Obesity and Associated Comorbidities.

Obesity currently affects 78.6 million people (33%) in the United States and is expected to increase to over 50% of the population by 2030. This epidemic is fueled by the growing rate of obesity in ad...

Association between cardiorespiratory fitness and metabolic risk factors in a population with mild to severe obesity.

Previous literature suggests the beneficial effects of fitness on abdominal obesity may be attenuated in obesity and abolished in severe obesity. It is unclear whether the beneficial association betwe...

Association between different combination of measures for obesity and new-onset gallstone disease.

Body mass index(BMI) is a calculation index of general obesity. Waist circumference(WC) is a measure of body-fat distribution and always used to estimate abdominal obesity. An important trait of gener...

Medical and Biotech [MESH] Definitions

A condition of having excess fat in the abdomen. Abdominal obesity is typically defined as waist circumferences of 40 inches or more in men and 35 inches or more in women. Abdominal obesity raises the risk of developing disorders, such as diabetes, hypertension and METABOLIC SYNDROME X.

The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.

A sub-PHENOTYPE of obese individuals who have a risk for CARDIOVASCULAR DISEASES between that of healthy individuals with normal weight and unhealthy individuals with obesity.

BODY MASS INDEX in children (ages 2-12) and in adolescents (ages 13-18) that is grossly above the recommended cut-off for a specific age and sex. For infants less than 2 years of age, obesity is determined based on standard weight-for-length percentile measures.

Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.

More From BioPortfolio on "The Incretin Secretion in the Gut System Related to the Physiological Stimulus"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...


Searches Linking to this Trial